,i #aaith ,,congress #ast ,session ,h4 ,r4 #edfg ,,in ,,the ,,house ,,of ,,representatives ,september #ah1 #bjbe,ms4 ,johnson of ,texas 7for herself and ,mr4 ,kennedy of ,utah7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce1 and in addition to the ,committee on ,ways and ,means1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to amend title ,,xviii of the ,social ,security ,act to require coverage of drugs for autoimmune diseases and certain blood disorders under ,medicare part ,d4 #a4 ,short title ,this ,act may be cited as the ,patient ,access to ,autoimmune ,treatments ,act or the ,,paat ,act4 #b4 ,requiring coverage of drugs for autoimmune diseases and certain blood disorders under ,medicare part ,d ,section #ahfj;,d-#d of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#ajd7 is amended-- 7#a7 in subsection 7b77#c71 by adding at the end the following new subparagraph3 7,j7 ,required inclusion of certain drugs for autoimmune diseases and blood disorders 7i7 ,in general ,for #bjbg and each subsequent year1 a ,,pdp sponsor offering a prescription drug plan shall include each covered part ,d drug that is an autoimmune or blood disorder drug described in clause 7ii74 7ii7 ,autoimmune or blood disorder drug ,for purposes of clause 7i71 a drug described in this clause is a covered part ,d drug indicated and prescribed for the treatment of an autoimmune disease1 hemophilia1 or ,von ,willebrand disease4 2 and 7#b7 in subsection 7c7-- 7,a7 by redesignating paragraph 7#f71 as added by section #ejced of division ,e of the ,bipartisan ,budget ,act of #bjah 7,public ,law #aae-abc71 as paragraph 7#g72 and 7,b7 by adding at the end the following new paragraph3 7#h7 ,prohibition on use of prior authorization for certain autoimmune or blood disorder drugs ,for plan years beginning on or after ,january #a1 #bjbg1 a ,,pdp sponsor offering a prescription drug plan 7and an ,,ma organization offering an ,,ma-,,pd plan7 may not require1 with respect to an individual enrolled under such plan1 that prior authorization for an autoimmune or blood disorder drug 7as described in subsection 7b77#c77;,j77ii77 be obtained more than once during any #ab-month period unless such drug is-- 7,a7 typically used for a period of #ab months or less2 7,b7 an opioid1 a benzodiazepine1 a barbiturate1 or carisoprodol2 or 7,c7 a drug with respect to which a risk evaluation and mitigation strategy is required under ,section #eje-a of the ,federal ,food1 ,drug1 and ,cosmetic ,act4 4